Clinical trials
HIV-1 clinical trials
Below are recruiting hiv-1 clinical trials, each written for real people, not researchers. We’re tracking 79 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07293559Recruiting
Understanding infant feeding choices in women with HIV
This study looks at how women with HIV decide whether to breastfeed, and what support they get from healthcare providers and family. It aims to learn about their experiences and needs.
Los Angeles, CaliforniaAges Any age - NCT06902142Recruiting
HIV treatment study with Bictegravir medication monitoring
This study looks at how well HIV-1 patients take their medication (bictegravir/emtricitabine/tenofovir) and how that relates to how well the virus is controlled. It uses a special pill bottle cap that records when the bottle is opened, so the research team can see if the medicine is being taken as prescribed.
CaenAges 18 years+ - NCT03729752RecruitingPhase 1
PET scan to study an HIV-fighting antibody in the body
This Phase 1/early study uses a special PET scan to see where an HIV-targeting antibody (VRC01) goes in the body. The study may help researchers understand how well this antibody reaches HIV-related targets, which could guide future HIV treatments or vaccines.
San Francisco, CaliforniaAges 18 years+ - NCT05590455RecruitingPhase 2
Testing a TNF-blocking drug to reduce death in HIV and TB meningitis
This Phase 2 trial studies whether a TNF-blocking medicine can lower the risk of death in people with HIV who also have TB meningitis. You would receive standard TB meningitis treatment plus the study drug, if you meet the criteria.
Rio de JaneiroAges 18 years+ - NCT07643948Recruiting
How HIV Treatment Changes Affect Drug Resistance
This study follows people with HIV whose virus is well-controlled on current medications to understand how switching to a different HIV drug regimen affects the virus's ability to resist those drugs. The goal is to help doctors choose the safest treatment switches.
Hong Kong, Hong KongAges 18 years+ - NCT06252402RecruitingEarly Phase 1
CAR T cells for HIV: A new immunotherapy study
This trial tests a new type of immune cell, called a CAR T cell, that is designed to target and kill cells infected with HIV. It may help control the virus without needing to take HIV medication all the time.
Duarte, CaliforniaAges 18 years+ - NCT04513626RecruitingPhase 2
HIV trial testing doravirine plus raltegravir in adults
This Phase 2 trial studies whether switching to a combination of doravirine and raltegravir can safely maintain control of HIV in adults whose virus is already well suppressed. It may help people who are currently on stable HIV treatment and are not resistant to these specific medicines.
Paris, Île-de-France RegionAges 18 years+ - NCT07596888RecruitingPhase 1
Early safety study of experimental HIV treatment IAP-086-1
This is an early-stage trial testing a new experimental drug (IAP-086-1) in people with HIV who have their virus well-controlled on current medications. Researchers want to understand how safe the drug is and how the body handles it.
Chapel Hill, North CarolinaAges 18–70 - NCT07769983Enrolling by invitationPhase 1
HIV vaccine study for people on effective treatment
This study tests a new vaccine designed to help your immune system fight HIV better. It is for people with HIV who are already on effective antiretroviral therapy and have a well-controlled virus. The goal is to see if the vaccine is safe and boosts your body's natural defenses.
Bern, Canton of BernAges 18 years+ - NCT06127290Recruiting
HIV treatment study for people in Eastern Europe and Russia
This study looks at how well newer HIV medicines work in people starting treatment for the first time in Eastern Europe and Russia. It also checks for drug resistance to find better treatment strategies.
CologneAges 18 years+ - NCT04160455Recruiting
Study of GALIG proteins in adults with HIV on or off treatment
This study looks at how “GALIG” gene products affect the body’s internal recycling process (called autophagy) in people living with HIV. It may help researchers understand differences between people on HIV treatment, starting treatment, or not currently taking it.
OrléansAges 18 years+ - NCT06834113Recruiting
Testing pain relief from HIV shot location and virtual reality
This study looks at whether changing where you get your HIV injection (in the buttock area) and using a virtual reality headset during the shot can reduce pain. It is for people whose HIV is well-controlled with the injectable medicines cabotegravir and rilpivirine.
Orléans, LoiretAges 18 years+ - NCT06762054Recruiting
Better management for dolutegravir-resistant HIV
This trial tests better ways to manage HIV when the virus becomes resistant to dolutegravir (DTG), a key medicine. It is for people with high viral load despite being on DTG for at least six months.
KisumuAges 1 year+ - NCT06747507RecruitingPhase 3
Ndovu study: best HIV treatment for drug resistance
This trial is for people with HIV who are not responding well to the drug dolutegravir (DTG). It tests if switching to a different drug, darunavir/ritonavir (DRV/r), works better than continuing DTG when resistance has developed.
KisumuAges 3 years+ - NCT06774872RecruitingPhase 2
Comparing two-drug HIV maintenance treatments
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
Paris, Île-de-France RegionAges 18 years+ - NCT05136703Recruiting
Study depression treatment effects in people living with HIV
This study looks at how depression and its treatment may affect the brain and immune-related body systems in people with HIV. You may be eligible if you have depression and a well-controlled HIV viral load, and you can safely complete brain MRI scans.
Coral Gables, FloridaAges 18 years+ - NCT03174977RecruitingEarly Phase 1
How HIV medicine moves through the body on MRI scans
This early study measures how raltegravir (an HIV medicine) spreads in the body using a special scan called PET/MR. It may help doctors better understand how to deliver and monitor HIV treatment, even though it focuses on measuring drug behavior rather than curing HIV.
San Francisco, CaliforniaAges 18 years+ - NCT06507059RecruitingPhase 3
Injectable HIV treatment trial for people with unsuppressed virus
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
KeelungAges 18 years+ - NCT07308782RecruitingPhase 2
Testing a new HIV treatment in people not yet on therapy
This trial is testing an experimental HIV pill called CL-197. It's for people with HIV who have never taken any HIV medicines before. The study lasts about 2 weeks and aims to see how the drug works in the body.
BeijingAges 18–60 - NCT05985642Recruiting
HIV treatment interruption study for long-term participants
This study looks at people with HIV who have already taken a break from their HIV medications (called an analytic treatment interruption, or ATI) as part of another study. It aims to understand how well the body can control the virus during longer breaks from treatment, up to 96 weeks.
San Francisco, CaliforniaAges 18 years+ - NCT07181486RecruitingPhase 1
Safety study of a vaginal gel for healthy women
This trial tests a gel placed in the vagina to see if it is safe. Healthy women with regular periods who have a steady partner may join.
San Francisco, CaliforniaAges 18–45 - NCT06458504Recruiting
HIV infection and bone marrow health study
This study looks at how HIV infection affects the bone marrow's ability to make blood cells. Researchers will use bone marrow samples already taken from HIV-positive patients and compare them to samples from people without HIV.
Boulogne-BillancourtAges 18 years+ - NCT04892654RecruitingPhase 3
Doravirine plus dolutegravir switch for people with HIV
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
LondonAges 18 years+ - NCT07711223RecruitingPhase 1/Phase 2
New HIV pill compared to standard treatment for untreated adults
This trial compares a new HIV medication (ACC017) to an existing one (dolutegravir) in adults who have HIV but have never taken HIV drugs before. The goal is to see if the new pill works as well and is safe.
BeijingAges 18 years+
Hear when a new HIV-1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hiv-1?
- Yes. Clin2 currently lists 79 recruiting hiv-1 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv-1 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv-1 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.